Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

BioLineRx Ltd. BLRX

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.2M
▼ 95.9% YoY
$-2.0M
$-8.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 1.2M
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.2 · Net income -2.0
15.0M30.0M-25.0M-50.0M
20152018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−172 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -871.8% · Net -171.7%
-500%-1000%
201520202025
ROE
FY2024 · ROE -69.1%
-50%-100%-150%
201520202025
Three returns, three denominators.
Return on equityNot available: we don't have a clean profit figure for this period.

Return on equity has no reading this year — return on capital employed, just below, still does: -39%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -8.1
-20M-40M
201520202025

Total assetsUSD 40.9M
EquityUSD 18.2M
CashUSD 3.2M
Current ratio1.95×

Equity funds 44% of total assets.

The 11-year record

11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BLRX, 11-year financial record
Metric 20252024202320222021202020192018201720162015
Revenue $B0.00.00.00.00.0◌◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.0◌◌◌◌
Net income $B−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $0.00−0.01−0.06−0.03−0.04−0.12◌◌◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————
ROE %◌−69.1−189.2−42.0−60.0−108.4−68.1−48.8−55.4−38.3−30.2

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 41 reconciliationsAUDITED

Reconciled in 11 of the 11 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. 14 checks were skipped: revenue is not tagged before 2021. 13 checks were skipped: EPS is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image